Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Jaguar Health, Inc.
Report date March 12, 2018 · Filed June 07, 2018
Section 16 reporting ended · disclosed 2018-06-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.40 · Expires 2027-08-02 | Direct | 12,965 |
Reported balance
After 2018-03-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-03-12 · Grant · Acquired 12,965 · Balance 12,965 F1: Granted pursuant to the Issuer's 2014 Equity Incentive Plan F2: All share numbers and the exercise price reflect the 1-for-15 reverse stock split effected on June 1, 2018. F3: The option grant was approved by the Issuer's board of directors on August 2, 2017, subject to shareholder approval of the amendment to the 2014 Stock Incentive Plan. The Issuer's shareholders approved the amendment on March 12, 2018. F4: Vests in equal monthly installments, beginning August 2, 2017, such that it is vested in full on the 3-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted pursuant to the Issuer's 2014 Equity Incentive Plan
F2: All share numbers and the exercise price reflect the 1-for-15 reverse stock split effected on June 1, 2018.
F3: The option grant was approved by the Issuer's board of directors on August 2, 2017, subject to shareholder approval of the amendment to the 2014 Stock Incentive Plan. The Issuer's shareholders approved the amendment on March 12, 2018.
F4: Vests in equal monthly installments, beginning August 2, 2017, such that it is vested in full on the 3-year anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2018 Filed Jun 7, 2018 01:43 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock Option (right to buy) · Derivative | 12,965 | $0.00 Strike: $8.40 | $0.00 |
DisclosureSEC source: 0001104659-18-038718 · a4.xml · derivative · entry 1 Yang Zhi · CIK 0001623220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,965 Underlying: Common Stock · 12,965 shares Expires 2027-08-02 F1 · security: Granted pursuant to the Issuer's 2014 Equity Incentive Plan F2 · security: All share numbers and the exercise price reflect the 1-for-15 reverse stock split effected on June 1, 2018. F3 · date: The option grant was approved by the Issuer's board of directors on August 2, 2017, subject to shareholder approval of the amendment to the 2014 Stock Incentive Plan. The Issuer's shareholders approved the amendment on March 12, 2018. F4 · derivative.exercise_date: Vests in equal monthly installments, beginning August 2, 2017, such that it is vested in full on the 3-year anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.